“Oncological” bevacizumab vs. “ophthalmological” ranibizumab: are they both for exudative-neovascular AMD?

被引：0
|
作者：
Jerzy Z. Nowak
机构：
[1] Medical University,Department of Pharmacology, Chair of Pharmacology and Clinical Pharmacology
来源：
Pharmacological Reports | 2011年 / 63卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：556 / 558
页数：2
相关论文
共 48 条
  • [1] "Oncological" bevacizumab vs. "ophthalmological" ranibizumab: are they both for exudative-neovascular AMD?
    Nowak, Jerzy Z.
    [J]. PHARMACOLOGICAL REPORTS, 2011, 63 (02) : 556 - 558
  • [2] Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
    Cho, Hyung
    Shah, Chirag P.
    Weber, Marissa
    Heier, Jeffrey S.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (08) : 1032 - 1035
  • [3] Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD
    Scholler, Andreas
    Richter-Mueksch, Sibylla
    Weingessel, Birgit
    Vecsei-Marlovits, Pia-Veronika
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 (11-12) : 355 - 359
  • [4] Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
    Maria Waizel
    Margarita G. Todorova
    Michael Masyk
    Katharina Wolf
    Annekatrin Rickmann
    Khaled Helaiwa
    Björn R. Blanke
    Peter Szurman
    [J]. BMC Ophthalmology, 17
  • [5] Ranibizumab and bevacizumab show equivalent effects on visual acuity in patients with neovascular AMD
    不详
    [J]. FORMULARY, 2011, 46 (06) : 203 - 203
  • [6] Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
    Waizel, Maria
    Todorova, Margarita G.
    Masyk, Michael
    Wolf, Katharina
    Rickmann, Annekatrin
    Helaiwa, Khaled
    Blanke, Bjoern R.
    Szurman, Peter
    [J]. BMC OPHTHALMOLOGY, 2017, 17
  • [7] Intravitreal Aflibercept in Eyes with Neovascular AMD Requiring Frequent Retreatment with Intravitreal Bevacizumab or Ranibizumab
    Thorell, Mariana Rossi
    Nunes, Renata Portella
    Gregori, Giovanni
    Feuer, William J.
    Rosenfeld, Philip J.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [8] Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
    Avery, Robert L.
    Castellarin, Alessandro A.
    Steinle, Nathan C.
    Dhoot, Dilsher S.
    Pieramici, Dante Joseph
    See, Robert
    Couvillion, Stephen
    Nasir, Ma'an A.
    Rabena, Melvin D.
    Le, Kha
    Maia, Mauricio
    Visich, Jennifer E.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (12) : 1636 - 1641
  • [9] Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements
    Shah, A. R.
    Del Priore, L. V.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2009, 93 (08) : 1027 - 1032
  • [10] Response to Aflibercept After Frequent Re-treatment With Bevacizumab or Ranibizumab in Eyes With Neovascular AMD
    Thorell, Mariana R.
    Nunes, Renata Portella
    Chen, Gene W.
    Doshi, Rishi R.
    Dugar, Jyoti
    George, Mathew K.
    Kim, Brian T.
    Lowrance, Matthew D.
    Modi, Dimple
    Nahas, Zayna
    Gregori, Giovanni
    Yehoshua, Zohar
    Feuer, William
    Rosenfeld, Philip J.
    [J]. OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2014, 45 (06): : 526 - 533
12345